Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.